GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Cryostem Corp (OTCPK:CRYO) » Definitions » EV-to-EBITDA

American Cryostem (American Cryostem) EV-to-EBITDA : -0.32 (As of Jun. 09, 2024)


View and export this data going back to 2010. Start your Free Trial

What is American Cryostem EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, American Cryostem's enterprise value is $1.17 Mil. American Cryostem's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-3.63 Mil. Therefore, American Cryostem's EV-to-EBITDA for today is -0.32.

The historical rank and industry rank for American Cryostem's EV-to-EBITDA or its related term are showing as below:

CRYO's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.385
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-09), American Cryostem's stock price is $0.0001. American Cryostem's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.074. Therefore, American Cryostem's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


American Cryostem EV-to-EBITDA Historical Data

The historical data trend for American Cryostem's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Cryostem EV-to-EBITDA Chart

American Cryostem Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -41.99 -26.67 -20.39 -26.97 -7.22

American Cryostem Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.71 -7.22 -10.38 -5.38 -4.09

Competitive Comparison of American Cryostem's EV-to-EBITDA

For the Biotechnology subindustry, American Cryostem's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Cryostem's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, American Cryostem's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where American Cryostem's EV-to-EBITDA falls into.



American Cryostem EV-to-EBITDA Calculation

American Cryostem's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1.170/-3.632
=-0.32

American Cryostem's current Enterprise Value is $1.17 Mil.
American Cryostem's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Cryostem  (OTCPK:CRYO) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

American Cryostem's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0001/-0.074
=At Loss

American Cryostem's share price for today is $0.0001.
American Cryostem's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.074.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


American Cryostem EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of American Cryostem's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


American Cryostem (American Cryostem) Business Description

Traded in Other Exchanges
N/A
Address
1 Meridian Road, Suite 5, Eatontown, NJ, USA, 07724
American Cryostem Corp is a biotechnology company which standardizes adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The company acts as an innovator of adipose tissue and stem cell platform technologies. It provides the clinical grade, adipose tissue and adult stem cell collection, processing, and cryo-preservation technology, providing first-in-class cellular therapy products and services for patients, physicians and researchers based on the transformative science of Regenerative and Personalized Medicine.
Executives
John S Arnone director, officer: Chairman 111 GREAT NECK RD, GREAT NECK NY 11021
Anthony Francis Dudzinski director, officer: COO 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Acs Global, Inc. 10 percent owner 188 E. BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Christopher Joseph Neill 10 percent owner 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Hector Medina director, 10 percent owner, officer: President and Director 1206 STAGECOACH TRAIL LOOP, CHULA VISTA CA 91915